Navigation Links
NITTO DENKO Avecia Inc. Introduces Dedicated Pre-Clinical Oligonucleotide Service, OliGrow
Date:5/13/2013

Milford, Massachusetts (PRWEB) May 13, 2013

NITTO DENKO Avecia Inc., an industry leader in therapeutic nucleic acid manufacturing and development services, is proud to introduce a new pre-clinical oligonucleotide synthesis service, OliGrow. Combining phase appropriate quality and purity standards with a high level of customer service, the Avecia OliGrow team delivers pre-clinical oligonucleotides at µmol to mmol scales, with affordable pricing and fast turn around times.

OliGrow offers custom DNA and RNA with standard chemical modifications, along with advanced solutions for more specialized needs, including oligonucleotide conjugates and specialty amidites. Its experts operate within a dedicated facility at Avecia’s FDA- registered Cincinnati, OH plant, and use instrumentation, methods, and analytics designed for scalability and consistency throughout the development process.

As the only oligonucleotide CMO that can deliver both the first µmols of pre-clinical material and bring a program through to commercialization, Avecia OliGrow creates value for its customers by building compound knowledge from the very start, avoiding future surprises and costly technical transfers and process changes.

Dr. Marc Lemaitre, Avecia’s VP for New Businesses and Services, says the company is very proud to bring this small scale service under the same roof as the large scale, clinical productions. “Previous options to bridge the gap between pure research and clinical production in the oligo space were largely accomplished through collaborations and partnerships between multiple companies. But now are pleased to offer OliGrow as a unique, one- stop option for oligonucleotide developers.”

ABOUT NITTO DENKO Avecia Inc.

NITTO DENKO Avecia, Inc. is a drug development and manufacturing services company located in Milford, MA, and is a part of Nitto Denko Corporation, Japan’s leading diversified materials manufacturer. Avecia is a recognized leader process development, manufacture, and related services for DNA and RNA-based therapeutics. All services are offered, from preclinical testing to post-commercial launch of innovative oligonucleotide-based therapeutics. To see what Avecia can do for your business, visit http://www.avecia.com

Read the full story at http://www.prweb.com/releases/2013/5/prweb10715509.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. GeneTex Introduces New Mouse Monoclonal Antibody Against the Ten-Eleven Translocation 1 (TET1) Protein for DNA Methylation/Epigenetics Research
2. Montclair Breast Center introduces 3D Mammography.
3. Adult Acne Treatment, Probiotic Action Introduces their Antibiotic-Free Acne Treatment
4. ChanTest Introduces the CardioChannelGram™ and SaVety Assessment
5. Diagenode Introduces Innovative Bioruptor® Pico for Micro-Volume Chromatin and DNA Shearing
6. Texas Fertility Center Introduces Oncofertility Education Program for Physicians and Patients
7. Finesse Solutions Introduces SmartParts for Intelligent Universal Controllers
8. Cearna Introduces Product Designed to Reduce Patient’s Recovery Time From Facial Plastic Surgery
9. Rigaku Introduces New Instruments at Pittcon 2013
10. GIN Introduces Advanced Robotics and Dispensing Technology at BVS La Jolla Biotech Day
11. FMC BioPolymer Introduces Its New Portfolio of Nature-Based Nutritional Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... At its ... announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief research scientist of ... been selected for membership in ARCS Alumni Hall of Fame . ASTER ...
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit ... 7th and 8th June 2018 in San Francisco, CA. The Summit brings together current ... several distinguished CEOs, board directors and government officials from around the world to address ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017  SkylineDx ... London (ICR) and University of Leeds ... to risk-stratify patients with multiple myeloma (MM), in a multi-centric ... The University of Leeds is the ... UK, and ICR will perform the testing services to include ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and ... of osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular ...
Breaking Biology Technology:
(Date:8/15/2017)... , Aug. 15 2017   ivWatch LLC , a ... intravenous (IV) therapy, today announced receipt of its ISO 13485 Certification, ... by the International Organization for Standardization (ISO®). ... ivWatch Model 400 Continuous Monitoring device for the early ... "This is an ...
(Date:5/23/2017)... May 23, 2017  Hunova, the first robotic gym for the rehabilitation ... officially launched in Genoa, Italy . The first 30 ... and the USA . The technology was developed and ... by the IIT spin-off Movendo Technology thanks to a 10 million euro ... Release, please click: ...
(Date:4/19/2017)... April 19, 2017 The global ... landscape is marked by the presence of several large ... held by five major players - 3M Cogent, NEC ... accounted for nearly 61% of the global military biometric ... in the global military biometrics market boast global presence, ...
Breaking Biology News(10 mins):